Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 7/20 | 0.51 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.50 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 3/20 | 0.44 |
| ▸ | NAT1 | P18440 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MAX | P61244 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482962 | 1.00 | MTOR (0.51) | MTORRPTORMLST8PIM1NAT1 | |
| SCHEMBL3482965 | 1.00 | MTOR (0.51) | MTORRPTORMLST8PIM1NAT1 | |
| SCHEMBL12979174 | 0.90 | IGF1R (0.52) | MTORPIM1NAT1HPGDGSK3B | |
| SCHEMBL861523 | 0.90 | IGF1R (0.52) | MTORPIM1NAT1HPGDGSK3B | |
| SCHEMBL861524 | 0.90 | IGF1R (0.52) | MTORPIM1NAT1HPGDGSK3B | |
| SCHEMBL3482803 | 0.80 | CSNK2B (0.43) | HPGDGSK3B | |
| SCHEMBL3482801 | 0.80 | CSNK2B (0.43) | HPGDGSK3B | |
| SCHEMBL3483235 | 0.80 | CSNK2B (0.43) | HPGDGSK3B | |
| SCHEMBL860236 | 0.76 | PARP1 (0.43) | GSK3B | |
| SCHEMBL860313 | 0.75 | PIK3CG (0.47) | MTORRPTORMLST8PIM1NAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | MTOR 174/4885RPTOR 2006/4885MLST8 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.